BioSpace News Archive

As a company dedicated to expediting research related to the treatment and prevention of Alzheimer’s Disease, Cognitive Clinical Trials (CCT) is fundamentally changing the way these types of studies are performed.

Starting today, California doctors will have to check a patient’s prescription history before prescribing addictive opioids and other controlled substances. The legislation is the culmination of a years-long fight by families impacted by opioid abuse to mandate doctors consult a state prescription database in order to reduce opioid overprescribing and save lives.

Novavax, Inc. today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.

SELLAS Life Sciences Group, Inc. today announced that data from the Phase 2b trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) for the treatment of women with triple-negative breast cancer (TNBC) will be presented in a poster presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 9-11, 2018 in Washington, D.C.

Nightstar Therapeutics plc today announced the closing of its underwritten public offering of 4,600,000 American Depositary Shares (“ADSs”) representing 4,600,000 ordinary shares, at a public offering price of $18.00 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 ADSs.

Cytokinetics, Incorporated today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will participate in a fireside chat at the Chardan Genetic Medicines Conference in New York City on Tuesday, October 9, 2018.

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 4:15 p.m. ET at the Westin Grand Central, New York.

Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Akebia’s common stock on September 28, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third quarter ended September 30, 2018 is expected to be in the range of $34.3 million to $34.7 million.